Our December 2023 Gastroenterology Month in Review features a pair of American Gastroenterological Association guidelines and articles from the fourth installment of Qazi Corner.
Katie Falloon, MD, discusses findings from the SEQUENCE study, the importance of treatment positioning, and what direct data from head-to-head studies contributes to this understanding.
Ustekinumab is currently the only anti-interleukin therapy approved for the treatment of ulcerative colitis, but given the superior performance of risankizumab in CD patients, it will be interesting to see data regarding its efficacy in UC.